A track record of prior competency that is above and beyond the norm is what hiring managers look for when they recruit "top talent", as recruiters like to say. Usually "top talents" can command a premium in the market place because everybody wants to employ them. We can equate these "top talents" to top quality stocks. You often hear dividend investors talk about how top dividend growth stocks are "always too expensive". That comment usually refers to the yield for the stock being lower than average, which in the case of a quality stock just represents a greater anticipation of future growth.
Two years after originally announcing it, Medtronic and IBM Watson have launched their joint platform the Sugar.IQ, a digital diabetes assistant. "It is designed for people who are currently using Guardian Connect; so made for people on multiple daily injections. It is a personal assistant a little bit like Alexa or Siri," Huzefa Neemuchwala, global head of digital health solutions and AI at Medtronic, said in a Facebook live informational session. "It is an intelligent assistant that keeps track of all of your information and has all of your information in one place. Then through Watson technology we use this information to power insights so we can better manage your diabetes so that you can spend more time in range."
Today at RSNA, IBM Watson Health is announcing two new products, and showcasing a variety of partnerships and clients that are using our advanced technologies to improve the way radiologists deliver care. We are delighted to announce these collaborations at RSNA highlighting our advancements in medical imaging globally," said Anne Le Grand, General Manager, Imaging, Life Sciences, and Oncology, IBM Watson Health. "From helping clinicians to identify potential missed findings to seeing a summary view of patient records quickly, our innovative technologies are at the forefront of Watson Health's mission to help enable clinicians to more effectively respond to the world's most pressing health challenges." Clinical Review 3.0, a tool recently launched in the UK that analyzes medical imaging studies and their associated reports to identify potentially missed findings, facilitating higher quality and more comprehensive care for the patient. IBM Watson Health Imaging has recently engaged with Fortrus Ltd, to grow upon the reseller's strong relationship with the UK public sector, which includes a single supplier outcome-based Managed Services framework. The Imaging AI Marketplace is a single-source solution designed to help simplify the complex process of locating, purchasing, deploying and managing the vast array of AI imaging applications. The Imaging AI Marketplace is carefully curated and contains only FDA-cleared solutions alongside Watson Health developed AI solutions. Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional imaging, also recently signed an exclusive joint development agreement to develop an artificial intelligence software solution to support prostate cancer diagnostics and monitoring, utilizing MR imaging. This deal extends their earlier collaboration regarding liver cancer signed in January 2018. In addition, 4ways, a fast-growing private teleradiology network in the UK that enables UK-based radiologists to work remotely over a leading technology platform, has committed to underpin its ambitious growth strategy with IBM Watson Health's Merge PACS 8.0 platform, upgrading its current platform to support their business growth. Merge PACS is a workflow platform that is designed to help simplify physicians' reading activities and can empower IT leaders with advanced control of the flow of studies throughout the enterprise. "We're committed to constantly investing in and upgrading our IT provision to be able to offer our clients and partners the very best service.
FDA Commissioner Scott Gottlieb is making the most of his final week at the agency. In the month that has passed since Gottlieb rattled the medical device industry with news of his impending resignation, the commissioner has issued 18 public statements pertaining to nearly all corners of the agency's realm, from food, tobacco, and cosmetics to drugs and devices. Friday is Gottlieb's last day on the job. On Tuesday, Gottlieb said the agency will consider a new regulatory framework for reviewing medical devices that use advanced artificial intelligence algorithms. AI has been making headlines in medtech for a while now, and this is certainly not the first time FDA has turned its attention to how AI-based medical devices should be regulated.
Algorithms based on machine learning and deep learning, intended for use in diagnostic imaging, are moving into the commercial pipeline. However, providers will have to overcome multiple challenges to incorporate these tools into daily clinical workflows in radiology. There now are numerous algorithms in various stages of development and in the FDA approval process, and experts believe that there could eventually be hundreds or even thousands of AI-based apps to improve the quality and efficiency of radiology. The emerging applications based on machine learning and deep learning primarily involve algorithms to automate such processes in radiology as detecting abnormal structures in images, such as cancerous lesions and nodules. The technology can be used on a variety of modalities, such as CT scans and X-rays.